Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1

Trial Profile

Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions
  • Acronyms OPTIVISMO-1
  • Most Recent Events

    • 09 Jan 2019 Planned End Date changed from 1 Jul 2020 to 1 Aug 2020.
    • 09 Jan 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020.
    • 09 Jan 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top